Pandemic Hits Perrigo Q1 Top And Bottomline

Loading...
Loading...
  • Perrigo Company plc PRGO reported Q1 net sales were $1.01 billion, a decrease of 6.8% year-on-year, missing the consensus of $1.02 billion.
  • Adjusted diluted EPS fell 25.4% to $0.50, well below the consensus of $0.57.
  • The reported declines in the first quarter were distorted by consumer pantry loading in the year-ago quarter and by a historically weak cough/cold season this year, both of which resulted from COVID-19.
  • Consumer Self-Care Americas segment Q1 net sales of $641 million were 8.6% lower than the prior-year quarter, with organic growth down 11.8%.
  • Consumer Self-Care International segment sales decreased 3.4% Y/Y to $370 million, with organic growth down 9.1%.
  • Operating income of $51 million fell from $86 million a year ago. Adjusted operating income came in at $118 million, lower than $151 million last year.
  • The results were impacted by lower net sales volumes leading to lower gross profit, divestitures, and higher operating expenses, including R&D investments.
  • Guidance: Perrigo reaffirmed its FY21 outlook and expected to deliver 3% organic net sales growth, 5% adjusted operating income growth.
  • It sees adjusted EPS of $2.50 to $2.70, in line with the consensus of $2.62.
  • Price Action: PRGO shares are up 0.5% at $43.34 during the premarket trading on the last check Tuesday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...